<DOC>
	<DOC>NCT00045864</DOC>
	<brief_summary>The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.</brief_summary>
	<brief_title>Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion: Diagnosis: CD20+ Bcell nonHodgkin's lymphoma (NHL) classified as intermediate or highgrade according to the Working Formulation, subtypes D to H. Must have measureable progressive or refractory disease after no more than three prior chemotherapy regimens. Exclusion: Clinically significant cardiac dysfunction, or a history of myocardial infarction or heart failure within 6 months of first study treatment Clinically significant pulmonary dysfunction. Liver disease (note hepatitis C seropositive subjects may be enrolled if they have no active disease as demonstrated by undetectable HCV viral loads, biopsy showing no active disease, and/or history of normal transaminases on at least three different dates within one year of first study treatment). Symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism. History of autoimmune disease. History of positive serology for human immunodeficiency virus (HIV).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>Intermediate and High-Grade Non-Hodgkin's Lymphoma</keyword>
</DOC>